Momenta Pharmaceuticals, Inc. (MNTA) Q1 2012 Earnings Call May 3, 2012 10:00 AM ET Executives Lora Pike – Senior Director, IR and Corporate Communications Craig Wheeler – President and CEO Rick Shea – SVP and CFO Analysts Sapna Srivastava – Goldman Sachs Ritu Baral – Canaccord Sumant Kulkarni – Bank of America Eric Schmidt – Cowen & Company Joseph Schwartz – Leerink Swann Presentation Operator
Previous Statements by MNTA
» Momenta Pharmaceuticals' Management Presents at Barclays Capital 2012 Global Healthcare Conference (Transcript)
» Momenta Pharmaceuticals CEO Presents at 2012 Citi Global Health Care Conference (Transcript)
» Momenta Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript
» Momenta Pharmaceuticals CEO Hosts Investor Conference Call to Discuss Follow-On Biologics Collaboration with Baxter (Transcript)
Before we begin, I’d like to mention that our call today will contain forward-looking statements about management’s future expectations, beliefs, plans and prospects. These forward-looking statements include comments about our enoxaparin sodium injection commercial prospects, our generic Copaxone program, ANDA review and patent litigation expectations and our other product development plans and expectations, including our future development, partnering and commercialization potential for our development programs.Such forward looking statements involve known and unknown risks, uncertainties, and other factors referred to in the company’s annual report on Form 10-K for the year ended December 31, 2011, filed with the Securities and Exchange Commission under the section Risk Factors as well as other documents that may be filed by Momenta from time to time with the SEC. As a result of such risks, the company’s actual results may differ materially from those we will be discussing. We’re providing the information on this conference call as of today’s date and we assume no obligation to update these comments. With that, I will now turn the call over to Craig. Craig Wheeler Thank you, Lora and good morning, everyone. Thanks for joining us. I’d like to start today by introducing all of you to Lora Pike, our new Senior Director of Investor Relations and Corporate Communications. I’m sure many of you already know Lora from her Vertex experience. She has tremendous depth in the IR area and we’re thrilled that she has chosen to join us here at Momenta. I’d also like to personally thank Beverly Holley, who has retired after a long and productive career, including the past five years ably serving as Momenta’s Senior IR executive. Her counsel will be missed and we offer her our best wishes. Now, turning to the business at hand. The first quarter of 2012 was a period of significant transition for the company. First, in January, as a result of the Court of Appeals staying the preliminary injunction on our competitors’ launch of their generic Lovenox, Momenta’s enoxaparin revenues transition from a hybrid royalty profit to a tiered royalty-based arrangement.
Second, in February, our follow-on biologics deal with Baxter officially closed and we commenced our work in collaboration with Baxter to bring up the sixth biosimilar and potentially interchangeable drugs to market.Third, during the first quarter, we began a research effort to apply our recently acquired Sialic Switch technology to the development of a sialylated related IDIG product. And, finally we are presenting – presently screening patients in the next few weeks and expect to initiate dosing in a proof of concept phase I & II clinical trial for our novel drug M402, in people with metastatic pancreatic cancer. I’d like to focus my prepared remarks today on a review of our three core areas, complex generics, Biosimilars and novel drugs. First, our market drug, enoxaparin. We reported $22 million in enoxaparin product revenues, based on Sandoz reported net sales of $176 million. Our revenues included a hybrid profit share on net sales through late January, then a royalty in the balance of the quarter. Our reduced level of enoxaparin revenues in the first quarter of 2012 reflected the launch of our competitors in enoxoparin and the relaunch of Sanofi Winthrop’s authorized generic, Lovenox, which impacted Sandoz’s enoxaparin unit volume and pricing. Rick will provide additional context around these results in his remarks. It’s important to note that as of today, the U. S. Court of Appeals has not issued a ruling regarding their rationale for staying in the preliminary injunction against Amphastar and Watson. That ruling could come at any time. In the underlying Enoxaparin patent litigation, there is a claims construction hearing tomorrow, May 4th. And the trial is scheduled for October of this year. So until we get a ruling in this litigation, Amphastar and Watson’s generic Lovenox is being marketed at risk. On the commercial front, it’s still too early to predict how competition will evolve, but in the absence of an injunction, we expect to see an increasingly competitive environment. As I said last quarter, competition is a fact of life in the generics business. We’re proud that the Sandoz Momenta ANDA for generic Lovenox was the first to receive FDA approval and was the sole generic Lovenox for more than 18 months. Read the rest of this transcript for free on seekingalpha.com